

# katia Mareschi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8564467/publications.pdf>

Version: 2024-02-01

45  
papers

3,281  
citations

236925

25  
h-index

254184

43  
g-index

47  
all docs

47  
docs citations

47  
times ranked

4345  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Novel Xeno-Free Method to Isolate Human Endometrial Mesenchymal Stromal Cells (E-MSCs) in Good Manufacturing Practice (GMP) Conditions. International Journal of Molecular Sciences, 2022, 23, 1931.	4.1	0
2	HSCT with Mismatched Unrelated Donors (MMUD): A Comparison of Different Platforms for GvHD Prophylaxis. Transplantation, 2022, 3, 51-67.	0.6	0
3	A New Human Platelet Lysate for Mesenchymal Stem Cell Production Compliant with Good Manufacturing Practice Conditions. International Journal of Molecular Sciences, 2022, 23, 3234.	4.1	6
4	A New Human Platelet Lysate for Mesenchymal Stem Cell Production Compliant with Good Manufacturing Practice Conditions Preserves the Chemical Characteristics and Biological Activity of Lyo-Secretome Isolated by Ultrafiltration. International Journal of Molecular Sciences, 2022, 23, 4318.	4.1	3
5	Precision Medicine in Osteosarcoma: MATCH Trial and Beyond. Cells, 2021, 10, 281.	4.1	5
6	Genetic and Epigenetic Characterization of a Discordant KMT2A/AFF1-Rearranged Infant Monozygotic Twin Pair. International Journal of Molecular Sciences, 2021, 22, 9740.	4.1	1
7	Organotypic spinal cord cultures: An <em>in vitro</em> 3D model to preliminary screen treatments for spinal muscular atrophy. European Journal of Histochemistry, 2021, 65, .	1.5	3
8	Inactivated Platelet Lysate Supports the Proliferation and Immunomodulant Characteristics of Mesenchymal Stromal Cells in GMP Culture Conditions. Biomedicines, 2020, 8, 220.	3.2	4
9	Cytokine-Induced Killer (CIK) Cells, In Vitro Expanded under Good Manufacturing Process (GMP) Conditions, Remain Stable over Time after Cryopreservation. Pharmaceuticals, 2020, 13, 93.	3.8	13
10	Human endogenous retrovirus, HERV-P and HERV-R in pediatric leukemia patients. Journal of Hematopathology, 2019, 12, 51-56.	0.4	2
11	Human Endogenous Retrovirus-H and K Expression in Human Mesenchymal Stem Cells as Potential Markers of Stemness. Intervirology, 2019, 62, 9-14.	2.8	11
12	In Vitro Mesenchymal Progenitor Cell Expansion is a Predictor of Transplant-related Mortality and acute GvHD III-IV After Bone Marrow Transplantation in Univariate Analysis: A Large Single-Center Experience. Journal of Pediatric Hematology/Oncology, 2019, 41, 42-46.	0.6	4
13	Analysis of Mesenchymal Stromal Cell Engraftment After Allogeneic HSCT in Pediatric Patients: A Large Multicenter Study. Journal of Pediatric Hematology/Oncology, 2018, 40, e486-e489.	0.6	2
14	Cytokines induced killer cells produced in good manufacturing practices conditions: identification of the most advantageous and safest expansion method in terms of viability, cellular growth and identity. Journal of Translational Medicine, 2018, 16, 237.	4.4	8
15	A novel TaqMAMA assay for allelic discrimination of TLR9 rs352140 polymorphism. Journal of Virological Methods, 2017, 243, 25-30.	2.1	6
16	Expression of the pol gene of human endogenous retroviruses HERV-K and -W in leukemia patients. Archives of Virology, 2017, 162, 3639-3644.	2.1	29
17	Development of a Low-Cost Stem-Loop Real-Time Quantification PCR Technique for EBV miRNA Expression Analysis. Molecular Biotechnology, 2016, 58, 540-550.	2.4	3
18	Immunoregulatory effects on T lymphocytes by human mesenchymal stromal cells isolated from bone marrow, amniotic fluid, and placenta. Experimental Hematology, 2016, 44, 138-150.e1.	0.4	71

#	ARTICLE	IF	CITATIONS
19	CMV induces HERV-K and HERV-W expression in kidney transplant recipients. <i>Journal of Clinical Virology</i> , 2015, 68, 28-31.	3.1	47
20	H3K4me1 marks DNA regions hypomethylated during aging in human stem and differentiated cells. <i>Genome Research</i> , 2015, 25, 27-40.	5.5	119
21	Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions. <i>Cytotherapy</i> , 2014, 16, 750-763.	0.7	55
22	Human mesenchymal stromal cell transplantation modulates neuroinflammatory milieu in a mouse model of amyotrophic lateral sclerosis. <i>Cytotherapy</i> , 2014, 16, 1059-1072.	0.7	79
23	Validation of analytical methods in compliance with good manufacturing practice: a practical approach. <i>Journal of Translational Medicine</i> , 2013, 11, 197.	4.4	23
24	Multipotent Mesenchymal Stromal Stem Cell Expansion by Plating Whole Bone Marrow at a Low Cellular Density: A More Advantageous Method for Clinical Use. <i>Stem Cells International</i> , 2012, 2012, 1-10.	2.5	63
25	Validation of analytical methods in GMP: the disposable Fast Read 102Â® device, an alternative practical approach for cell counting. <i>Journal of Translational Medicine</i> , 2012, 10, 112.	4.4	27
26	Myogenic Potential of Whole Bone Marrow Mesenchymal Stem Cells In Vitro and In Vivo for Usage in Urinary Incontinence. <i>PLoS ONE</i> , 2012, 7, e45538.	2.5	40
27	The <i>MET</i> oncogene transforms human primary bone-derived cells into osteosarcomas by targeting committed osteo-progenitors. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 1322-1334.	2.8	27
28	Mesenchymal stromal cell transplantation in amyotrophic lateral sclerosis: a long-term safety study. <i>Cytotherapy</i> , 2012, 14, 56-60.	0.7	181
29	Intracellular reactive oxygen species are required for directional migration of resident and bone marrow-derived hepatic pro-fibrogenic cells. <i>Journal of Hepatology</i> , 2011, 54, 964-974.	3.7	109
30	Dissection of the Biphasic Nature of Hypoxia-Induced Motogenic Action in Bone Marrow-Derived Human Mesenchymal Stem Cells. <i>Stem Cells</i> , 2011, 29, 952-963.	3.2	51
31	Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A Phase I clinical trial. <i>Experimental Neurology</i> , 2010, 223, 229-237.	4.1	333
32	Mesenchymal stem cells for ALS patients. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2009, 10, 123-124.	2.1	16
33	Stem cells in amyotrophic lateral sclerosis: state of the art. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 1245-1258.	3.1	16
34	Multipotent mesenchymal stem cells from amniotic fluid originate neural precursors with functional voltage-gated sodium channels. <i>Cytotherapy</i> , 2009, 11, 534-547.	0.7	53
35	Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis. <i>Neurobiology of Disease</i> , 2008, 31, 395-405.	4.4	269
36	Stem cell treatment in Amyotrophic Lateral Sclerosis. <i>Journal of the Neurological Sciences</i> , 2008, 265, 78-83.	0.6	205

#	ARTICLE	IF	CITATIONS
37	Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential. <i>Gut</i> , 2008, 57, 223-231.	12.1	248
38	Bone Marrow Mesenchymal Stem Cells from Healthy Donors and Sporadic Amyotrophic Lateral Sclerosis Patients. <i>Cell Transplantation</i> , 2008, 17, 255-266.	2.5	75
39	Neural differentiation of human mesenchymal stem cells: evidence for expression of neural markers and eag K <sup>+</sup> channel types. <i>Experimental Hematology</i> , 2006, 34, 1563-1572.	0.4	134
40	Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow. <i>Journal of Cellular Biochemistry</i> , 2006, 97, 744-754.	2.6	289
41	Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis. <i>Neurological Research</i> , 2006, 28, 523-526.	1.3	169
42	Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases</i> , 2003, 4, 158-161.	1.2	216
43	Association Between Elevated Prolactin Levels and Circulating Erythroid Precursors in Dialyzed Patients. <i>Proceedings of the Society for Experimental Biology and Medicine</i> , 2000, 223, 367-371.	1.8	13
44	Tumor-Associated Transforming Growth Factor- $\beta^2$ and Interleukin-10 Contribute to a Systemic Th2 Immune Phenotype in Pancreatic Carcinoma Patients. <i>American Journal of Pathology</i> , 1999, 155, 537-547.	3.8	208
45	Bone Marrow Stroma-Derived Prolactin Is Involved in Basal and Platelet-Activating Factor-“Stimulated In Vitro Erythropoiesis. <i>Blood</i> , 1997, 90, 21-27.	1.4	45